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ABSTRACT
DNA gyrase is the only topoisomerase able to
introduce negative supercoils into DNA. Absent in
humans, gyrase is a successful target for antibac-
terial drugs. However, increasing drug resistance is
a serious problem and new agents are urgently
needed. The naturally-produced Escherichia coli
toxin CcdB has been shown to target gyrase by
what is predicted to be a novel mechanism. CcdB
has been previously shown to stabilize the gyrase
‘cleavage complex’, but it has not been shown to
inhibit the catalytic reactions of gyrase. We present
data showing that CcdB does indeed inhibit the
catalytic reactions of gyrase by stabilization of the
cleavage complex and that the GyrA C-terminal
DNA-wrapping domain and the GyrB N-terminal
ATPase domain are dispensable for CcdB’s action.
We further investigate the role of specific GyrA
residues in the action of CcdB by site-directed
mutagenesis; these data corroborate a model for
CcdB action based on a recent crystal structure of a
CcdB–GyrA fragment complex. From this work, we
are now able to present a model for CcdB action that
explains all previous observations relating to CcdB–
gyrase interaction. CcdB action requires a con-
formation of gyrase that is only revealed when DNA
strand passage is taking place.
INTRODUCTION
The development and spread of antibiotic resistance
among bacteria has become a major health and economic
burden [http://www.who.int/topics/drug_resistance/en/ (1)].
The majority of antimicrobials are directed at a small group of
well-validated targets, suggesting that these are the most effec-
tive means to kill cells. As a result, research into these targets,
either in the development of novel inhibitors or modiﬁcation of
existing agents, is crucial for future drug development.
The DNA topoisomerases are well-validated drug targets
(2–5). Topoisomerases resolve the topological problems
created by the double-helical structure of DNA in essential
cellular processes. They act by forming a transient single-
or double-stranded break in DNA, and catalysing passage
of a second strand or DNA duplex through the break
prior to resealing the DNA backbone (6). One of the best-
characterized topoisomerases is bacterial DNA gyrase,
which is a type IIA topoisomerase (i.e. it makes double-strand
breaks in DNA) and is unique in its ability to introduce nega-
tive supercoils into DNA. Gyrase is found almost exclusively
in bacteria, where it is essential to survival, and has been
shown to be a very good target for antimicrobial drugs (2,5).
Escherichia coli gyrase has two subunits, GyrA (97 kDa)
and GyrB (90 kDa), and functions as a heterotetramer
(A2B2). Each of the subunits has two distinct domains, the
N- and C-terminal domains (GyrA-NTD, GyrA-CTD,
GyrB-NTD and GyrB-CTD). The GyrA-NTD is the DNA
cleavage-religation domain and houses the active-site
tyrosines that form covalent linkages to DNA in the cleavage
reaction. The GyrA-CTD is a DNA-wrapping domain that
confers gyrase’s unique ability to introduce negative super-
coils into DNA. The GyrB-NTD is an ATPase domain,
which is required for DNA supercoiling. The GyrB-CTD
mediates the GyrA–GyrB interaction, provides residues for
the cleavage/religation reaction and is postulated to aid in
the DNA-wrapping process (7). The mechanism of DNA
supercoiling catalysed by gyrase involves a series of coordi-
nated steps. The enzyme binds a DNA duplex (the ‘G’ or
‘gate’ segment) across the head-dimer interface (DNA gate)
formed by the GyrA-NTDs. The region of DNA adjacent to
this is wrapped around the GyrA-CTD, and forms a crossover
(positive node) in which the ‘transported’ or ‘T’ segment lies
across the G segment. ATP binds to the GyrB monomers and
causes dimerization, trapping the T segment. The G segment
is cleaved in both strands and is covalently attached to the
protein at its 50 ends. Conformational changes lead to opening
of the DNA gate. The T segment passes into the GyrA cavity,
the G segment is religated and the T segment released
through the bottom gate (primary-dimer interface). ATP
hydrolysis is thought to stimulate strand passage and is
required for resetting of the enzyme for another cycle (6,8).
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inhibit DNA gyrase. The aminocoumarins are naturally-
occurring antibiotics that act by competitively inhibiting the
ATPase reaction but have received limited clinical use (5).
The quinolones are synthetic compounds that stabilize the
‘cleavage complex’ of gyrase. The newer ﬂuoroquinolones
e.g. ciproﬂoxacin (CFX), have been widely applied clinically
in the treatment of bacterial infections (9). However a variety
of quinolone-resistant strains have been isolated that exhibit
multiple mechanisms of resistance (10).
Microcin B17 and CcdB are two naturally-produced
proteinaceous inhibitors of gyrase, which are plasmid-
encoded toxins and, like quinolones, stabilize the cleavage
complex of gyrase (2). Microcin B17 (MccB17) is a post-
translationally modiﬁed peptide that is thought to act during
the strand passage step of gyrase-catalysed supercoiling,
although its precise mode of action is not known (11,12,13)
CcdB is the toxin component of the ccd toxin-antitoxin
(TA) module. TA modules are best-characterized by their
roles in the process of post-segregational killing of plasmid-
cured cells but are also believed to be involved in stress
responses (14,15). In the process of post-segregational kill-
ing, the modules are encoded on a plasmid and their efﬁcacy
relies on the differential stability of the toxin (stable) and
antitoxin (unstable). The antitoxin is rapidly degraded, with
loss of constitutive expression of the operon as a result of
loss of the plasmid, and the toxin is released to act on its
target (14). The ccd module is found on the F plasmid with
CcdB being the toxin and CcdA the antitoxin (13). Like the
quinolones, CcdB has been shown to poison gyrase by stabi-
lizing the cleavage complex (16–18), causing a ‘road-block’
to cellular polymerases (18), leading to double-strand DNA
breaks, and induction of the SOS response (19) and ultimately
cell death. The resemblance ends there, as there is no cross-
resistance between mutants (16,18) and there are differences
in the ATP requirement for cleavage complex stabilization
(17,18,20), suggesting that CcdB acts by a novel mechanism.
A structure was published for CcdB in 1999 (21) and, using
the existing structure for the GyrA-NTD (22), a model for
CcdB action was proposed (21). The model suggested that
a dimeric CcdB binds within the cavity formed by the
GyrA dimer, but only when the DNA gate is open, as steric
conﬂicts would prevent the interaction with the gate closed
(21). This places the three C-terminal residues of CcdB,
which are critical to its toxicity (23), in close proximity to
the GyrA Arg462 residue, which, when mutated, has been
shown to confer resistance to CcdB (16,17). Resistance is
also conferred by mutation of Gly214 of GyrA to Glu (24),
which does not lie in the proposed CcdB binding site (21).
The observation that CcdB and GyrA inefﬁciently form
their complex in vitro, with a denaturation/renaturation treat-
ment of the proteins being required to form the complex (25),
supported the model that CcdB only bound to a transiently-
revealed conformation of GyrA. A structure of CcdB with
a fragment of GyrA (GyrA14; a fragment containing the
bottom gate of GyrA-NTD) was published recently showing
a globally symmetric complex, with an asymmetric centre
where the GyrA Arg462 residue stacks between the Trp99
residues of the CcdB monomers (26). This supports the
previous model (21), which suggests that a conformational
change involving DNA gate opening is required for CcdB
binding. However, other work has indicated that CcdB and
gyrase can bind efﬁciently without a conformational change
(27). Although alluded to, it has never been shown whether
CcdB can inhibit the catalytic reactions of gyrase. To accom-
modate these observations two complexes between CcdB and
GyrA have been proposed (27).
In this paper, we have investigated the action of CcdB
against gyrase using biochemical assays. We show that CcdB
action requires a conformation of gyrase that allows strand
passage and that stabilization of the gyrase cleavage complex
by CcdB leads to inhibition of the catalytic reactions of
gyrase. The role of the GyrA Arg462 residue in CcdB binding
has been further investigated by site-directed mutagenesis.
This work supports the structural data and a model for a sin-
gle complex in CcdB action, and provides further information
for the rational design of novel antimicrobials to target DNA
gyrase.
MATERIALS AND METHODS
Proteins
DNA gyrase subunits GyrA and GyrB were produced as
described previously (28) with some material being a kind
gift from Mrs A. J. Howells (John Innes Enterprises Limited,
Norwich). Site-directed mutagenesis was performed using the
QuickChange kit (Stratagene) and plasmid pPH3 (29) as a
template. The mutations were conﬁrmed by sequencing
(JIC Genome Laboratory). Topoisomerase IV (topo IV) was
produced as described previously (30) and was supplied by
John Innes Enterprises. Topoisomerase II (topo II) was pro-
duced as described previously (31) and was a kind gift
from Dr Melisa Wall (JIC). CcdB was puriﬁed from strain
B462 (pULB2250), which has the ccdB gene under the
tight control of the tac promoter, using the published protocol
as a guide (32), with some modiﬁcations. Overnight cultures
were diluted 30-fold into Terriﬁc Broth plus ampicillin
(100 mg/ml) and grown at 30 C. After 4 h, over-expression
was induced by addition of isopropylthio-b-D-galactoside to
0.5 mM. After a further 3 h at 30 C, cells were harvested
by centrifugation. Cell pellets were resuspended in 5 ml of
50 mM Tris–HCl (pH 7.8), 1 mM EDTA, 1 mM DTT,
150 mM NaCl and 10% glycerol. The cells were disrupted
using a French press and the cell debris was pelleted by cen-
trifugation. The supernatant was dialysed against 50 mM
Tris–HCl (pH 8.0) and 150 mM NaCl. The protein sample
was applied to a HiPrep 26/60 Sephacryl S-200 High Resolu-
tion gel ﬁltration column (Pharmacia) at a ﬂow rate of 1 ml/
min with the same buffer. Fractions containing CcdB were
pooled and dialysed against 20 mM Tris–HCl (pH 8.0). The
dialysed sample was then applied to a MonoQ High Resolu-
tion 5/5 anion exchange column (Pharmacia) at a ﬂow rate of
1 ml/min with the same buffer. Proteins were eluted with a
0–0.5 M NaCl linear gradient; CcdB eluted at  0.2 M
NaCl. Fractions containing CcdB were pooled and dialysed
against 25 mM MOPS, at pH 7.0. The sample was applied
to an XK 16/20 column packed with CM Sepharose Fast
Flow cation exchange media (Pharmacia), at a ﬂow rate of
2 ml/min with the same buffer and eluted with a 0.1–0.3 M
NaCl linear gradient. CcdB was eluted at  0.16 M NaCl.
Fractions containing CcdB were pooled and dialysed against
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2 mM DTT, 1 mM EDTA and 10% glycerol]. CcdB was
judged to be >95% pure by SDS–PAGE with a typical
yield of 5 mg/l of culture. CcdA was puriﬁed from strain
SG22623 (pKK223CcdA), which has the ccdA gene under
the tight control of the tac promoter, using the published pro-
tocol as a guide (33). CcdA was judged to be >95% pure by
SDS–PAGE with a typical yield of 2 mg/l of culture. The
CcdB and CcdA over-producing strains and plasmids were
gifts from Dr L. Van Melderen (Brussels, Belgium).
DNA and drugs
Negatively supercoiled and relaxed pBR322 plasmid
DNA were kind gifts from Mrs A. J. Howells (John Innes
Enterprises). Linear pBR322 was generated by digesting
negatively supercoiled DNA with EcoRI (New England
BioLabs), followed by phenol extraction and ethanol precip-
itation. Positively supercoiled pBR322 was generated by
incubating relaxed pBR322 with a large excess of DNA
gyrase under relaxation conditions (no ATP): 35 mM Tris–
HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 5 mM DTT,
1.8 mM spermidine, 6.5% (v/v) glycerol, 0.36 mg/ml acety-
lated BSA for 3 h at 37 C, followed by phenol extraction
and ethanol precipitation. CFX (Bayer) was dissolved in water.
Enzyme assays
DNA gyrase supercoiling assays were carried out as
described previously (34), except that reactions were incu-
bated at 25 or 37 C for various times up to 4 h and contained
3.5 nM relaxed pBR322, 1.5–20 nM DNA gyrase and
0–12.5 mM CFX or CcdB, as indicated. DNA gyrase relaxa-
tion assays were carried as described previously (35), except
that reactions were incubated at 25 or 37 C for various times
up to 4 h and contained 3.5 nM negatively supercoiled
pBR322, 20–200 nM DNA gyrase and 0–12.5 mM CFX or
CcdB, as indicated. A novel high-throughput microtitre
plate-based ﬂuorescence assay was carried out as described
previously (36). Brieﬂy, a triplex-forming oligonucleotide
was immobilized onto the wells of a streptavidin-coated
microplate. Supercoiling assays (as described above) were
carried out in the wells using plasmid pNO1 as substrate
(37). Subsequent incubation at pH 5.0 enabled triplex forma-
tion between the oligonucleotide and supercoiled pNO1.
Unbound plasmid DNA was removed by washing and the
wells stained with SYBR Gold (Invitrogen) and the ﬂuores-
cence read using a SPECTRAmax Gemini ﬂuorimeter.
Topo IV and topo II relaxation assays were carried as
described previously (37,38). Drug-induced DNA cleavage
assays with gyrase were carried out as detailed above, except
for post treatment with SDS (0.2%) and proteinase K
(1 mg/ml) at 37 C for 30 min. Reversibility of CcdB-
stabilized cleavage complex assays were carried out as per
gyrase supercoiling assays, except that CFX and CcdB were
at 2 mM and there was post treatment with either water,
EDTA (10, 50 and 100 mM), NaCl (0.1, 0.5 and 1 M) or
CcdA (1, 2 and 5 mM), with duplicates of each incubated at
37 C and 80 C for 30 min, followed by a further treatment
with SDS (0.2%) and proteinase K (1 mg/ml) at 37 C for
30 min. With the exception of the ﬂuorescence assay, the
DNA products of all assays were analysed by electrophoresis
in 1% agarose gels. Ethidium bromide (1 mg/ml) was some-
times added to the gel and running buffer, as indicated.
Where required, the fraction of DNA distributed between
the various topological forms was quantiﬁed using GeneTools
software (Syngene). Where appropriate, data were ﬁtted
assuming simple 1:1 binding between ligand (CFX or CcdB)
and gyrase, i.e. we did not presume a particular mechanism of
binding. In one instance (Figure 5B) data were ﬁtted to
sigmoidal curves, i.e. indicating >1 binding site and
cooperativity.
RESULTS
Nucleotide-dependence of CcdB-stabilized cleavage
complexes of DNA gyrase
Previous work had reported a nucleotide-dependence for
CcdB stabilization of gyrase cleavage complexes (17,18).
With linear DNA as substrate, CcdB stabilization of cleavage
complexes is ATP-dependent; with negatively supercoiled
DNA, the presence of at least the non-hydrolysable analogue
of ATP, ADPNP (50-adenylyl b,g-imidodiphosphate), is
required (18). The nucleotide requirement for stabilization
of gyrase cleavage complexes with two other substrates,
relaxed DNA and positively supercoiled DNA, had not
been investigated.
CcdB’s nucleotide-dependence for stabilizing gyrase
cleavage complexes was investigated by adding CcdB to a
ﬁxed concentration of the enzyme with linear, negatively
supercoiled, positively supercoiled or relaxed DNA as sub-
strates, each in either the absence or presence of ATP or
ADPNP; CFX was used as a control. As reported previously
(17,18), CcdB required ATP with a linear DNA substrate and
at least ADPNP with a negatively supercoiled DNA substrate
(Figure 1). Relaxed and positively supercoiled DNA sub-
strates also showed ATP-dependence for stabilization of the
cleavage complex (Figure 1). CcdB would appear to require
nucleotide in order to stabilize the DNA gyrase cleavage
complex, under any conditions (but see below).
Estimation of IC50 value for CcdB in
comparison to CFX
Previous work, and that detailed in the previous section, has
highlighted signiﬁcant differences in the action of CcdB in
comparison to quinolones (17,18). We therefore assessed
the relative potency of the inhibitors by estimating a value
for the IC50 (inhibitor concentration required to see a 50%
reduction in activity) for cleavage complex stabilization.
CcdB’s ability to stabilize the gyrase cleavage complex
was investigated by titrating CcdB into a ﬁxed concentration
of gyrase and DNA. The linear DNA band was estimated as
a % of total DNA and the data plotted and ﬁtted to a 1:1
ligand-binding curve (Figure 2). IC50s were estimated to be
 190 nM and  680 nM for CFX and CcdB, respectively.
A further point to note is that the maximum level of linear
product for CcdB was lower than for CFX (Figure 2). Thus
CcdB is not as potent an inhibitor of gyrase as CFX and
stabilizes a lower proportion of the enzyme in the cleavage
complex (see Discussion).
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relaxation of DNA by CcdB
Previous work has shown that CcdB acts to poison gyrase by
stabilizing the cleavage complex (17,18). Although it has
been alluded to (27), data have never been published to
show whether CcdB can inhibit the catalytic reactions of
gyrase. The model for CcdB action involves it binding in
the GyrA cavity when the DNA gate is open and acting as
a wedge (21,26). If this is the case, how a T segment can
bypass this block is unclear; a model where there are two dis-
tinct CcdB–GyrA complexes has also been proposed (27). To
further examine this question, the supercoiling and relaxation
reactions of gyrase were challenged with CcdB.
CcdB’s ability to inhibit the supercoiling and relaxation
reactions of gyrase was investigated by titrating CcdB into
various concentrations of gyrase, with incubation at different
temperatures. In standard supercoiling assays at 37 Cw i t h
20 nM gyrase, a relaxed DNA substrate is completely
negatively supercoiled in 1 h; CFX inhibited this reaction
(Figure 3A). CcdB did not apparently inhibit this reaction
(Figure 3A) but did stabilize cleavage complex formation
(Figure 3B). The concentration of gyrase was reduced to
1.5 nM and the reactions incubated at 25 C, in order to
slow down the reaction. Under these conditions the relaxed
DNA substrate was fully negatively supercoiled in 4 h, and
both CFX and CcdB showed inhibition of the catalytic super-
coiling reaction of gyrase (Figure 3A). Control experiments
showed that this effect was not a consequence of the reaction
temperature but depended on the rate of the reaction (data not
shown). At these concentrations of gyrase, there are so few
CcdB-stabilized cleavage complexes that it is difﬁcult to
visualize them by ethidium staining (Figure 3B). Subsequent
detection using Southern blotting showed that CcdB
increased the intensity of the cleaved linear band (data not
shown). A ﬂuorescence-based microplate assay (36) was
used to better estimate the IC50s for supercoiling inhibition
by the two inhibitors (see Figure 5):  135 nM and
 2.98 mM, for CFX and CcdB, respectively.
In standard relaxation assays at 37 C with 20 nM gyrase, a
negatively supercoiled DNA substrate is completely relaxed
in 1 h. The concentration of gyrase was maintained but the
incubation temperature was reduced to 25 C, which meant
full relaxation took  4 h (Figure 4A). Both CFX and CcdB
completely inhibited this reaction (Figure 4A) by the stabil-
ization of cleavage complexes (Figure 4B). The ﬂuorescence-
based plate assay was used to obtain IC50s for inhibition of
relaxation under these conditions (Figure 5B):  2.7 mM
and  10.8 mM for CFX and CcdB, respectively. Note that
data for inhibition of supercoiling were ﬁtted to single expo-
nentials (Figure 5A) and data for inhibition of relaxation to
sigmoidal curves (Figure 5B). It is known that two molecules
of CFX are likely to bind to the gyrase–DNA complex (39)
and that this binding is cooperative; this cooperativity is
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Figure 1. Nucleotide-dependence of CcdB-stabilized, DNA gyrase-mediated
cleavage of DNA. Relaxed, negatively supercoiled ( ve s/c), linear or
positively supercoiled (+ve s/c) pBR322 (3.5 nM) was incubated with gyrase
(30 nM), either with no nucleotide, ATP (1.4 mM) or ADPNP (1.4 mM) and
either CFX (13.5 mM) or CcdB (3.6 mM), as indicated, for 1 h at 37 C.
Cleavage complexes were revealed by the addition of SDS and proteinase K
and incubation at 37 C for 30 min. DNA was subjected to phenol extraction
and analysed on 1% agarose gels. L, linear; N, nicked; R, relaxed; SC,
supercoiled.
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Figure 2. Estimation of IC50s for CcdB stabilization of the gyrase cleavage
complex. Relaxed pBR322 (3.5 nM) was incubated with gyrase (30 nM), ATP
(1.4 mM) and various concentrations of CFX (0, 0.01, 0.05, 0.1, 0.25, 0.5,
0.75, 1, 2.5, 5, 7.5 and 10 mM) or CcdB (0, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8
and 9 mM) as indicated, for 1 h at 37 C. Cleavage complexes were revealed
by the addition of SDS and proteinase K and incubation at 37 C for
30 min. DNA was subjected to phenol extraction and analysed on (A)1 %
agarose gels run in the presence of ethidium bromide (1 mg/ml). (B) The % of
linear DNA was quantified, data plotted and data fitted to single rectangular
hyperbolae.
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the steepness of the curve. CcdB is thought to bind as a dimer
to gyrase (26), although no cooperativity has been previously
reported (27); it is not clear why the CcdB curve in Figure 5B
shows a greater than ﬁrst-order dependence on CcdB concen-
tration.
For the ﬁrst time CcdB has been shown to inhibit both
of the catalytic reactions of DNA gyrase via stabilization of
the cleavage complex. Relaxation of negatively supercoiled
DNA by DNA gyrase is an ATP-independent reaction and
thus also indicates, in contrast to previous observations, that
CcdB does not have an absolute requirement for ATP to exert
its action.
The role of the GyrA-CTD in CcdB’s action
Previous work had reported that the 35 kDa GyrA-CTD, the
DNA-wrapping domain, was required for the action of CcdB
(18). In this work, linear DNA was used as a substrate and,
as such, the wrapping domain is essential to provide a node
that will facilitate opening of the DNA gate. Gyrase with a
truncated GyrA (A592B2) can still perform relaxation of
negatively supercoiled DNA in both an ATP-independent
(40) and ATP-dependent manner (41) manner. In both these
situations, a node can be formed by the DNA itself, without
the active help of the DNA-wrapping domain, thus allowing
strand passage. To explore the role of the GyrA-CTD, the
effect of CcdB on the reactions of the A592B2 complex
was investigated.
CcdB’s ability to stabilize the A592B2 cleavage complex
and inhibit the relaxation of negatively supercoiled DNA by
the A592B2 enzyme was investigated by titrating CcdB into a
ﬁxed concentration of A592B2 and DNA. CcdB stabilized the
A592B2 cleavage complex and inhibited the relaxation of
negatively supercoiled DNA by the enzyme (Figure 6). This
inhibition via cleavage complex stabilization by CcdB was
observed both in the presence (Figure 6) and the absence of
ATP (data not shown). (The streaking observed in panel A in
the presence of CFX is a common feature of experiments
involving GyrA59 and is likely to be associated with its
DNA-binding properties.) It should be noted that the concen-
tration of enzyme in these assays was 100 nM as the reactions
are inefﬁcient; hence, it is possible to see inhibition of the
catalytic reaction under these conditions. Therefore CcdB
does not require the GyrA-CTD for its action.
The role of the GyrB-NTD in CcdB’s action
Previous work had reported that ATP was a crucial element in
CcdBs action (17,18,20). With the observations detailed here
showing that CcdB inhibits the ATP-independent relaxation
reaction of gyrase, the requirement for ATP to allow CcdB
action is called into question. Gyrase with the GyrB ATPase
domain truncated (A2B472) can still relax negatively super-
coiled DNA in an ATP-independent reaction (42,43). In
this situation, a node can be formed by the DNA itself and
opening of the DNA gate can occur without the ATPase
domain. To investigate the importance of the GyrB-NTD in
CcdB’s action, reactions were carried out using A2B472.
CcdB’s ability to stabilize the A2B472 cleavage complex
and inhibit the relaxation of negatively supercoiled DNA
was investigated by titrating CcdB into a ﬁxed concentration
of the A2B472 enzyme and DNA. CcdB-stabilized the
A2B472 cleavage complex and inhibited the relaxation of
negatively supercoiled DNA by A2B472 (Figure 7). Thus,
CcdB does not require the GyrB-NTD, and thus ATP is not
an absolute requirement for CcdB’s action.
CcdB-stabilized cleavage complexes are irreversible
without the presence of CcdA
It is well known that CcdB-stabilized gyrase cleavage
complexes are reversible by CcdA (17,18). However, the
action of other agents, such as quinolones, can be reversed
by heat and EDTA treatments (44,45). Therefore, the ability
of various treatments to reverse CcdB-stabilized cleavage
complexes has been assessed.
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Figure 4. CcdB can inhibit catalytic relaxation of DNA by gyrase. Negatively
supercoiled pBR322 (3.5 nM) was incubated with gyrase (20 nM) and various
concentrations of CFX and CcdB (0, 0.1, 0.2, 0.5, 1, 2, 5 and 10 mM) as
indicated, for 4 h at 25 C. Assays were either (A) stopped or (B) cleavage
complexes were revealed by the addition of SDS and proteinase K and
incubation at 37 C for 30 min. DNA was subjected to phenol extraction and
analysed on 1% agarose gels run in the (A) absence or (B) presence of
ethidium bromide (1 mg/ml).
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Figure 3. CcdB can inhibit catalytic supercoiling of DNA by gyrase. Relaxed
pBR322 (3.5 nM) was incubated with gyrase (1.5 or 20 nM), ATP (1.4 mM)
and various concentrations of CFX and CcdB (0, 0.1, 0.2, 0.5, 1, 2, 5 and
10 mM) as indicated, for 1 h at 37 C (20 nM gyrase) or 4 h at 25 C (1.5 nM
gyrase). Assays were either (A) stopped or (B) cleavage complexes
were revealed by the addition of SDS and proteinase K and incubation at
37 C for 30 min. DNA was subjected to phenol extraction and analysed on
1% agarose gels run in the (A) absence or (B) presence of ethidium bromide
(1 mg/ml).
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assays where treated with various concentration of EDTA,
NaCl or CcdA and incubated at either 37 or 80 C to investi-
gate the requirements to reverse CcdB-stabilized cleavage
complexes. CcdB-stabilized cleavage complexes were only
reversed by the addition of equimolar, or greater, concentra-
tions of CcdA (Figure 8); EDTA, NaCl and heat treatment
had no effect (Figure 8). Cleavage stabilized with CFX was
reversed by EDTA and heat treatment (Figure 8). Therefore
CcdB-stabilized cleavage complexes are more stable than
-
-
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CcdB
-
-
(A) (B)
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N
Figure 5. Estimation of IC50s for CcdB inhibition of the catalytic reactions of DNA gyrase. Relaxed (A) or negatively supercoiled (B) pN01 (3.5 nM) was
incubated with gyrase [1.5 nM (A); 20 nM (B)], ATP [1.4 mM (A); 0 mM (B)] and various concentrations of CFX (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,
1.5, 2, 2.5, 5 and 10 mM) or CcdB (0, 0.1, 0.2, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 12.5 mM) as indicated, for 4 h at 25 C. DNA was subjected to phenol
extraction and analysed on 1% agarose gels, or triplex formation was quantitatively analysed by SYBR fluorescence and data plotted (36). Data were fitted with
(A) single exponential decay curves or (B) sigmoidal curves.
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Figure 6. CcdB can inhibit the ATP-dependent relaxation of DNA by an
A592B2 gyrase complex. Negatively supercoiled pBR322 (3.5 nM) was
incubated with A592B2 (100 nM), ATP (1.4 mM) and various concentrations
of CFX and CcdB (0, 0.1, 0.2, 0.5, 1, 2, 5 and 10 mM) as indicated, for 1 h at
37 C. Assays were either (A) stopped or (B) cleavage complexes were
revealed by the addition of SDS and proteinase K and incubation at 37 C for
30 min. DNA was subjected to phenol extraction and analysed on 1% agarose
gels run in the (A) absence or (B) presence of ethidium bromide (1 mg/ml).
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Figure 7. CcdB can inhibit the ATP-independent relaxation of DNA by an
A2B472 gyrase complex. Negatively supercoiled pBR322 (3.5 nM) was
incubated with A2B472 complex (200 nM) and various concentrations of CFX
and CcdB (0, 0.1, 0.2, 0.5, 1, 2, 5 and 10 mM) as indicated, for 2 h at 37 C.
Assays were either (A) stopped or (B) cleavage complexes were revealed by
the addition of SDS and proteinase K and incubation at 37 C for 30 min.
DNA was subjected to phenol extraction and analysed on 1% agarose gels run
in the (A) absence or (B) presence of ethidium bromide (1 mg/ml).
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by CcdA treatment.
Site-directed mutagenesis of GyrA Arg462 and Gly214
and biochemical analysis of their activity
Two mutations in GyrA have been isolated that confer
resistance to CcdB: GyrA Arg462Cys (16,17) and Gly214Glu
(24). The role of Arg462 is now well-established (26) and
biochemical characterization of the protein has been per-
formed indicating that CcdB is unable to bind to the mutant
protein (17,27). Still the curiosity remains that the same
mutation has been isolated a number of times, with the Arg
always being substituted to Cys (16,17). No biochemical
characterization of the GyrA Gly214Glu protein has been
performed and the basis of conferring resistance is unknown.
Therefore we have made GyrA proteins bearing mutations at
these positions (Arg462 to Cys, Ser and Ala, and Gly214 to
Glu and Ala) and analysed their properties.
The full-length gyrA gene, in plasmid pPH3 (29), was
subjected to site-directed mutagenesis. Wild-type and mutant
GyrA proteins were over-expressed and puriﬁed, with the
exception of the Gly214Glu protein, which over-expressed
poorly and did not bind to the puriﬁcation columns. This pro-
tein was assumed to be mis-folded. We found two popula-
tions of GyrA: one (minor) fraction, which bound to the
columns and behaved like the wild-type enzyme in assays;
the other (major) fraction failed to bind to columns and
could not be puriﬁed, suggesting that this was a mis-folded
mutant protein.
Reconstituted gyrase with the puriﬁed mutant GyrA pro-
teins showed comparable supercoiling activity to wild-type
GyrA (data not shown). CcdB was able to stabilize cleavage
complexes with the wild-type and Gly214Ala enzymes
(Figure 9); the Arg462Cys, Arg462Ser and Arg462Ala
enzymes were refractory to CcdB (Figure 9). CcdB’s effect
on the supercoiling reaction mirrored that of its stabilization
of the cleavage complex with only the wild-type and
Gly214Ala enzymes being inhibited by CcdB (data not
shown). These data therefore show that GyrA Arg462 is criti-
cal for stabilizing the CcdB–GyrA complex and that substitu-
tions other than Cys at 462 (e.g. Ser and Ala) also result in
CcdB-resistant GyrA. These data also suggest that Gly214
is not directly involved in CcdB–GyrA interaction.
DISCUSSION
DNA gyrase is a well-validated drug target in antimicrobial
therapies. As with all drugs, the development of resistance
is a problem that needs to be overcome and thus work to
maintain the usefulness of such drugs and targets is of
paramount importance. Bacteria themselves are excellent
providers of antibiotics and, although clinically the most
successful agents that target gyrase are synthetic (i.e. quino-
lones), there are many naturally-produced toxins that target
gyrase. One of these, CcdB, is designed to target E.coli
gyrase and kill the cell for the means of selﬁsh maintenance
of plasmid DNA, but its action is not yet fully understood. In
this paper, we have investigated the mode of action of CcdB
and have rationalized the behaviour of this inhibitor in terms
of a model for its action on gyrase. Type IIA topoisomerases
share high levels of sequence homology (46) and gyrase and
topo IV are targeted by the same classes of drugs (4,47,48).
We have therefore also challenged topo IV from E.coli and
topo II from Saccharomyces cerevisiae with CcdB in relaxa-
tion and cleavage assays. With topo II we found no evidence
of inhibitory activity; with topo IV we found inhibition of
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Figure 9. The effect of GyrA mutations on stabilization of the cleavage
complex by CcdB. Relaxed pBR322 (3.5 nM) was incubated with various
gyrase enzymes (wild-type or mutants, 20 nM), ATP (1.4 mM) and various
concentrations of CFX and CcdB (0, 0.1, 0.2, 0.5, 1, 2, 5 and 10 mM), for 1 h
at 37 C, as indicated. Cleavage complexes were revealed by the addition of
SDS and proteinase K and incubation at 37 C for 30 min. DNA was subjected
to phenol extraction and analysed on 1% agarose gels run in the presence of
ethidium bromide (1 mg/ml).
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Figure 8. CcdB-stabilized DNA gyrase cleavage complexes are only reversed
by CcdA. Relaxed pBR322 (3.5 nM) was incubated with gyrase (20 nM),
ATP (1.4 mM) and either no inhibitor (Control), CFX (2 mM) or CcdB (2 mM)
for 1 h at 37 C. Assays were treated with either water, EDTA (10, 50 and 100
mM), NaCl (0.1, 0.5 and 1 M) or CcdA (1, 2 and 5 mM), with repeats of each
incubated at 37 Co r8 0  C for a further 30 min. Cleavage complexes were
revealed by the addition of SDS and proteinase K and incubation at 37 C for
30 min. DNA was subjected to phenol extraction and analysed on 1% agarose
gels run in the presence of ethidium bromide (1 mg/ml).
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(10 mM) with no evidence of cleavage complex formation
(data not shown).
Quinolones and other gyrase-speciﬁc agents, such as the
bacterial toxins CcdB and MccB17, inhibit gyrase by stabiliz-
ing the covalent complex between the enzyme and cleaved
DNA. Previous work has suggested that CcdB shows sig-
niﬁcant differences in its action when compared with quino-
lones. For example, CcdB action was thought to be ATP- (or
ADPNP-) dependent and require >160 bp of DNA (17,18).
Also CcdB was not known to inhibit the catalytic reactions
of gyrase. To account for these observations it was suggested
that two modes of CcdB binding to gyrase occur (20,27): a
complex with GyrA that is non-inhibitory, and a complex
with gyrase (A2B2) that stabilizes the cleavage complex.
In this paper, we have shown that ATP (or ADPNP) is not
required for CcdB action and, under appropriate conditions,
inhibition of gyrase-catalysed supercoiling and relaxation
can be detected. Furthermore, we found that neither the
GyrA-CTD (DNA-wrapping domain) nor the GyrB-NTD
(ATPase domain) is required. Taken together we propose
that CcdB’s action on gyrase can be explained by the
model shown in Figure 10. Here the CcdB dimer binds within
the GyrA cavity only when the DNA gate is open, thus form-
ing a complex in which the DNA gate, and hence the broken
G segment, is wedged open; several cycles of gyrase action
may be required prior to CcdB binding. This complex
(6b in Figure 10) can only form during strand passage (super-
coiling or relaxation reactions) and is inefﬁciently formed,
relying on a transiently-revealed conformation of the enzyme.
The effect of CcdB binding is to stabilize the cleavage com-
plex thus preventing strand passage (and hence supercoiling/
relaxation). This complex can still undergo ATP hydrolysis
cycles, albeit at a reduced rate (27). This complex is
extremely stable (27) and we have found that it can only be
reversed by the addition of CcdA (Figure 8). Such a mode of
action is entirely consistent with the recently-published crys-
tal structure of the complex between CcdB and GyrA14 (26).
GyrA
GyrB
G segment T segment
**
+2 ATP
(1) (2) (3) (4)
(6b)
(5) (6a) (7)
-1 ADP, 
Pi
-1 ADP, 
Pi
CcdB
-2 ADP, 
2 Pi
-2 ADP, 
2 Pi
**
+2 ATP
(6c)
* *
* * *
* *
*
-1 ADP, 
Pi
Figure 10. Model for CcdB action. The individual components (1) free in solution (7,50) come together (2) to form the holoenzyme with the G segment binding
across the DNA gate (8). (3) The DNA is wrapped by the GyrA-CTD to present the T segment over the G segment and a positive node is formed. (4) Upon ATP
binding, the GyrB monomers dimerise and (5) the G segment is cleaved and the DNA gate opens. Either (6a) ‘top-down’ passage of the T segment occurs upon
hydrolysis of a single ATP or (6b) CcdB accesses its binding site to stabilize the cleavage complex. (7) The DNA gate closes, the G segment is religated and the T
segment passes out through the bottom gate, with hydrolysis of the second ATP resetting the enzyme. (6c) A futile ATP hydrolysis/ATP binding cycle can occur
as per Kampranis et al. (27). Several cycles of (5) to (6a) transition may occur prior to CcdB binding in a (5) to (6b) transition.
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reported from earlier work stems from the fact that the con-
formation of gyrase required for CcdB binding occurs much
more efﬁciently in the presence of nucleotide (i.e. as part of
the supercoiling cycle; Figure 10) than in its absence. How-
ever, this conformation can still be accessed in the absence
of nucleotide when the enzyme is relaxing negatively super-
coiled DNA.
To test the proposed mode of interaction of CcdB with
GyrA, we made mutations at residues in GyrA known to con-
fer CcdB resistance (Arg462 and Gly214). We found that
substitutions at GyrA Arg462 rendered the enzyme CcdB-
resistant, consistent with its role in the interaction with
Trp99 of CcdB (26). Substitution of Ala at Gly214 had no
effect on GyrA; substitution of Glu produced an unstable
protein that we could not purify. We therefore suggest that
the Gly214Glu mutation affects GyrA folding and, in vivo,
the protein is active but very inefﬁcient at forming complexes
with CcdB.
Complexes between CcdB and GyrA alone have been
reported previously; this is surprising given that GyrA is a
very stable dimer (49); however, these data can be rational-
ized in relation to the model in Figure 10. Maki et al. (50)
found that cells over-producing CcdB had <1% of the super-
coiling activity seen in normal cells, but that extracts from
these cells could not inhibit puriﬁed gyrase. Further, Maki
et al. (51) have shown that such supercoiling-deﬁcient
gyrase–CcdB complexes can be rescued in vitro by CcdA.
These results can be explained by CcdB binding to GyrA
as it is being translated and before it has a chance to dimerize;
addition of CcdB to puriﬁed gyrase results in inefﬁcient
inhibition of supercoiling, as we have observed. Bahassi
et al. (25) found that the inactive GyrA–CcdB complex
could be reconstituted if GyrA was denatured and renatured:
such treatment would dissociate the GyrA dimer and allow
access of CcdB to its binding site upon refolding. Kampranis
et al. (27) showed, using surface-plasmon resonance, that
CcdB could bind to GyrA (or its N-terminal domain,
GyrA59) immobilized on a Biacore chip (Kds 10
 10 M).
Under these conditions, it is likely that at least some of the
GyrA protein could be immobilized as a monomer or as an
open dimer thus exposing the CcdB binding surface. Thus
the reports of two complexes between CcdB and gyrase are
likely to only reﬂect the possibility of CcdB binding to mono-
meric GyrA and to a conformation of gyrase revealed during
the topoisomerase cycle; these are likely to be the same
complex, i.e. that shown in Figure 10.
Two further features of CcdB–gyrase interaction deserve
comment. It has been reported that CcdB interaction requires
>160 bp of DNA to interact with gyrase (18). Referring to
Figure 10, this can be simply explained by the need to have
DNA long enough to form G and T segments and thus trigger
the conformational changes required for strand passage
that allow CcdB binding. It has also been shown that
ADPNP can promote CcdB-stabilized cleavage only with
negatively supercoiled DNA (18). However, in this paper
we have shown that CcdB action is nucleotide-independent,
providing that strand passage is able to occur (Figure 4).
We suggest that the earlier observations are a consequence
of the ‘bottom-up’ strand passage that occurs during relaxa-
tion of negatively supercoiled DNA by gyrase, generating
intermediate 5 from 7 in Figure 10. The presence of
ADPNP stabilizes this intermediate by closing the ATP-
operated clamp. Under these conditions the T segment is in
the upper part of the gyrase cavity, clear of the CcdB binding
site permitting binding of the toxin. With other substrates
(e.g. positively supercoiled DNA) ADPNP is more likely to
trap intermediate 6a, where the T segment may occlude the
CcdB binding site.
The mode of action of CcdB suggested in Figure 10 is
quite unlike that of quinolones, which are thought to bind
to a pocket involving GyrA, GyrB and DNA, prior to DNA
cleavage and without the requirement of DNA-wrapping
[Figure 10, step 2; (52)]. There is currently no structural
information on the binding of MccB17 to gyrase, but it is
thought that this toxin also binds during DNA strand passage
by gyrase in a complex involving the GyrB-CTD (11,12). The
action of CcdB on gyrase shares a number of similarities with
that of MccB17: both toxins appear to bind to a transient
intermediate that is revealed during strand passage and are
rather inefﬁcient inhibitors of the enzyme allowing several
strand passage cycles before a substantial amount of cleavage
complex is trapped. Whereas the MccB17 binding site
involves GyrB, GyrA would appear to be the exclusive target
for CcdB. Despite its comparative inefﬁciency of action,
CcdB is an effective toxin that is essentially irreversible in
its action; small molecule inhibitors based on CcdB would
be promising candidates for novel drugs.
ACKNOWLEDGEMENTS
A.B.S. was funded by a BBSRC-CASE studentship, sup-
ported by the BBSRC and GlaxoSmithKline. The authors
thank Lionel Costenaro, Remy Loris and Olivier Pierrat for
comments on the manuscript. Funding to pay the Open
Access publication charges for this article was provided by
BBSRC.
Conflict of interest statement. None declared.
REFERENCES
1. Howard,D.H. (2004) Resistance-induced antibiotic substitution.
Health Econ., 13, 585–595.
2. Maxwell,A. (1999) DNA gyrase as a drug target. Biochem. Soc.
Trans., 27, 48–53.
3. Hande,K.R. (1998) Clinical applications of anticancer drugs targeted to
topoisomerase II. Biochim. Biophys. Acta, 1400, 173–184.
4. Pommier,Y., Pourquier,P., Fan,Y. and Strumberg,D. (1998) Mechanism
of action of eukaryotic DNA topoisomerase I and drugs targeted to the
enzyme. Biochim. Biophys. Acta, 1400, 83–105.
5. Maxwell,A. and Lawson,D.M. (2003) The ATP-binding site of type II
topoisomerases as a target for antibacterial drugs. Curr. Top.
Med. Chem., 3, 283–303.
6. Corbett,K.D. and Berger,J.M. (2004) Structure, molecular mechanisms,
and evolutionary relationships in DNA topoisomerases. Annu.
Rev. Biophys. Biomol. Struct., 33, 95–118.
7. Chatterji,M., Unniram,S., Maxwell,A. and Nagaraja,V. (2000) The
additional 165 amino acids in the B protein of Escherichia coli DNA
gyrase have an important role in DNA binding. J. Biol. Chem.,
275, 22888–22894.
8. Heddle,J.G., Mitelheiser,S., Maxwell,A. and Thomson,N.H. (2004)
Nucleotide binding to DNA gyrase causes loss of DNA wrap.
J. Mol. Biol., 337, 597–610.
Nucleic Acids Research, 2006, Vol. 34, No. 17 46759. Drlica,K. and Malik,M. (2003) Fluoroquinolones: action and resistance.
Curr. Top. Med. Chem., 3, 249–282.
10. Ruiz,J. (2003) Mechanisms of resistance to quinolones:
target alterations, decreased accumulation and DNA gyrase protection.
J. Antimicrob. Chemother., 51, 1109–1117.
11. Pierrat,O.A. and Maxwell,A. (2003) The action of the bacterial toxin
microcin B17: insight into the cleavage-religation reaction of DNA
gyrase. J. Biol. Chem., 278, 35016–35023.
12. Pierrat,O.A. and Maxwell,A. (2005) Evidence for the role of DNA
strand passage in the mechanism of action of microcin B17 on DNA
gyrase. Biochemistry, 44, 4204–4215.
13. Ogura,T. and Hiraga,S. (1983) Mini-F plasmid genes that couple host
cell division to plasmid proliferation. Proc. Natl Acad. Sci. USA, 80,
4784–4788.
14. Hayes,F. (2003) Toxins-antitoxins: plasmid maintenance, programmed
cell death, and cell cycle arrest. Science, 301, 1496–1499.
15. Couturier,M., Bahassi,E.M. and Van Melderen,L. (1998) Bacterial
death by DNA gyrase poisoning. Trends Microbiol., 6, 269–275.
16. Bernard,P. and Couturier,M. (1992) Cell killing by the F plasmid CcdB
protein involves poisoning of the DNA-topoisomerase II complex.
J. Mol. Biol., 226, 735–745.
17. Bernard,P., Ke ´zdy,K.E., Van Melderen,L., Steyaert,J., Wyns,L.,
Pato,M.L., Higgins,N.P. and Couturier,M. (1993) The F plasmid CcdB
protein induces efficient ATP-dependent DNA cleavage by gyrase.
J. Mol. Biol., 234, 534–541.
18. Critchlow,S.E., O’Dea,M.H., Howells,A.J., Couturier,M., Gellert,M.
and Maxwell,A. (1997) The interaction of the F-plasmid killer protein,
CcdB, with DNA gyrase: induction of DNA cleavage and blocking of
transcription. J. Mol. Biol., 273, 826–839.
19. Karoui,H., Bex,F., Dre `ze,P. and Couturier,M. (1983) Ham22, a miniF
mutation which is lethal to host cell and promotes recA-dependent
induction of lambdoid prophage. EMBO J., 2, 1863–1868.
20. Scheirer,K. and Higgins,N.P. (1997) The DNA cleavage reaction
of DNA gyrase. Comparison of stable ternary complexes formed
with enoxacin and CcdB protein. J. Biol. Chem., 272, 27202–27209.
21. Loris,R., Dao-Thi,M.-H., Bahassi,E.M., Van Melderen,L.V.,
Poortmans,F., Liddington,R.C., Couturier,M. and Wyns,L. (1999)
Crystal structure of CcdB, a topoisomerase poison from E. coli.
J. Mol. Biol., 285, 1667–1677.
22. Morais Cabral,J.H., Jackson,A.P., Smith,C.V., Shikotra,N., Maxwell,A.
and Liddington,R.C. (1997) Structure of the DNA breakage-reunion
domain of DNA gyrase. Nature, 388, 903–906.
23. Bahassi,E.M., Salmon,M.A., Van Melderen,L., Bernard,P. and
Couturier,M. (1995) F plasmid CcdB killer protein: ccdB gene mutants
coding for non-cytotoxic proteins which retain their regulatory
functions. Mol. Microbiol., 15, 1031–1037.
24. Miki,T., Park,J.A., Nagao,K., Murayama,N. and Horiuchi,T. (1992)
Control of segregation of chromosomal DNA by sex factor F in
Escherichia coli. J. Mol. Biol., 225, 39–52.
25. Bahassi,E.M., O’Dea,M.H., Allali,N., Messens,J., Gellert,M. and
Couturier,M. (1999) Interaction of CcdB with DNA gyrase.
Inactivation of GyrA, poisoning of the gyrase–DNA complex, and the
antidote action of CcdA. J. Biol. Chem., 274, 10936–10944.
26. Dao-Thi,M.H., Van Melderen,L., De Genst,E., Afif,H., Buts,L.,
Wyns,L. and Loris,R. (2005) Molecular basis of gyrase poisoning by
the addiction toxin CcdB. J. Mol. Biol., 348, 1091–1102.
27. Kampranis,S.C., Howells,A.J. and Maxwell,A. (1999) The interaction
of DNA gyrase with the bacterial toxin CcdB: evidence for the
existence of two gyrase–CcdB complexes. J. Mol. Biol., 293,
733–744.
28. Maxwell,A. and Howells,A.J. (1999) Overexpression and purification
of bacterial DNA gyrase. In Bjornsti,M.-A. and Osheroff,N. (eds), DNA
Topoisomerase Protocols I. DNA Topology and Enzymes. Humana
Press, Totowa, New Jersey, pp. 135–144.
29. Hallett,P., Grimshaw,A.J., Wigley,D.B. and Maxwell,A. (1990)
Cloning of the DNA gyrase genes under tac promoter control:
overproduction of the gyrase A and B proteins. Gene, 93, 139–142.
30. Peng,H. and Marians,K.J. (1993) Escherichia coli topoisomerase IV.
J. Biol. Chem., 268, 24481–24490.
31. Lindsley,J.E. (1999) Overexpression and purification of
Saccharomyces cerevisiae DNA topoisomerase II from yeast. Meth.
Mol. Biol., 94, 187–197.
32. Steyaert,J., Van Melderen,L., Bernard,P., Thi,M.H.D., Loris,R.,
Wyns,L. and Couturier,M. (1993) Purification, circular dichroism
analysis, crystallization and preliminary X-ray diffraction analysis of
the F plasmid CcdB killer protein. J. Mol. Biol., 231, 513–515.
33. Van Melderen,L., Dao Thi,M.H., Lecchi,P., Gottesman,S.,
Couturier,M. and Maurizi,M.R. (1996) ATP-dependent degradation of
CcdA by Lon protease. J. Biol. Chem., 271, 27730–27738.
34. Mizuuchi,K., Mizuuchi,M., O’Dea,M.H. and Gellert,M. (1984) Cloning
and simplified purification of Escherichia coli DNA gyrase A and B
proteins. J. Biol. Chem., 259, 9199–9201.
35. Reece,R.J. and Maxwell,A. (1989) Tryptic fragments of the
Escherichia coli DNA gyrase A protein. J. Biol. Chem., 264,
19648–19653.
36. Maxwell,A., Burton,N.P. and O’Hagan,N. (2006) High-throughput
assays for DNA gyrase and other topoisomerases. Nucleic Acids Res.,
in press.
37. Hiasa,H., Yousef,D.O. and Marians,K.J. (1996) DNA strand cleavage is
required for replication fork arrest by a frozen
topoisomerase-quinolone-DNA ternary complex. J. Biol. Chem.,
271, 26424–26429.
38. Roca,J., Berger,J.M., Harrison,S.C. and Wang,J.C. (1996) DNA
transport by a type II topoisomerase: direct evidence for a two-gate
mechanism. Proc. Natl Acad. Sci. USA, 93, 4057–4062.
39. Critchlow,S.E. and Maxwell,A. (1996) DNA cleavage is not required
for the binding of quinolone drugs to the DNA gyrase–DNA complex.
Biochemistry, 35, 7387–7393.
40. Reece,R.J. and Maxwell,A. (1991) Probing the limits of the DNA
breakage-reunion domain of the Escherichia coli DNA gyrase A
protein. J. Biol. Chem., 266, 3540–3546.
41. Kampranis,S.C. and Maxwell,A. (1996) Conversion of DNA gyrase
into a conventional type II topoisomerase. Proc. Natl Acad. Sci. USA,
93, 14416–14421.
42. Brown,P.O., Peebles,C.L. and Cozzarelli,N.R. (1979) A topoisomerase
from Escherichia coli related to DNA gyrase. Proc. Natl Acad. Sci.
USA, 76, 6110–6114.
43. Gellert,M., Fisher,L.M. and O’Dea,M.H. (1979) DNA gyrase:
purification and catalytic properties of a fragment of gyrase B protein.
Proc. Natl Acad. Sci. USA, 76, 6289–6293.
44. Gellert,M., Mizuuchi,K., O’Dea,M.H., Itoh,T. and Tomizawa,J. (1977)
Nalidixic acid resistance: a second genetic character involved in DNA
gyrase activity. Proc. Natl Acad. Sci. USA, 74, 4772–4776.
45. Sugino,A., Peebles,C.L., Kruezer,K.N. and Cozzarelli,N.R. (1977)
Mechanism of action of nalidixic acid: purification of Escherichia coli
nalA gene product and its relationship to DNA gyrase and a novel
nicking-closing enzyme. Proc. Natl Acad. Sci. USA, 74, 4767–4771.
46. Caron,P.R. (1999) Appendix: compendium of DNA topoisomerase
sequences. In Bjornsti,M.-A. and Osheroff,N. (eds), DNA
Topoisomerase Protocols. DNA Topology and Enzymes. Humana Press,
Towata, NJ, Vol. 94, pp. 279–316.
47. Drlica,K. and Hooper,D.C. (2003) Mechanisms of quinolone action.
In Hooper,D.C. and Rubinstein,E. (eds), Quinolone Antimicrobial
Agents, 3rd edn. ASM Press, Washington DC, pp. 19–40.
48. Mitscher,L.A. (2005) Bacterial topoisomerase inhibitors: quinolone and
pyridone antibacterial agents. Chem. Rev., 105, 559–592.
49. Costenaro,L., Grossmann,J.G., Ebel,C. and Maxwell,A. (2005)
Small-angle X-ray scattering reveals the solution structure of the
full-length DNA gyrase A subunit. Structure, 13, 287–296.
50. Maki,S., Takiguchi,S., Miki,T. and Horiuchi,T. (1992) Modulation of
DNA supercoiling activity of Escherichia coli DNA gyrase by F
plasmid proteins. J. Biol. Chem., 267, 12244–12251.
51. Maki,S., Takiguchi,S., Horiuchi,T., Sekimizu,J. and Miki,T. (1996)
Partner switching mechanisms in activation and rejuvenation of
Escherichia coli DNA gyrase by F plasmid proteins, LetD (CcdB) and
LetA (CcdA). J. Mol. Biol., 256, 473–482.
52. Heddle,J. and Maxwell,A. (2002) Quinolone-binding pocket of DNA
gyrase: role of GyrB. Antimicrob. Agents Chemother., 46, 1805–1815.
4676 Nucleic Acids Research, 2006, Vol. 34, No. 17